Morten Frödin

Morten Frödin is an Associate Professor and group leader at the Biotech Research & Innovation Center (BRIC), University of Copenhagen, where he has been conducting research since 2004. His work primarily focuses on protein kinase signaling pathways and their roles in health and disease, particularly in cancer biology and genome engineering.

Education:

• MSc in Cell Biology from University of Copenhagen (1992)
• PhD in Molecular Biology from University of Copenhagen (1997) focusing on growth factor regulation of proliferation and differentiation of neuronal cells

Dr. Frödin's research interests center on cancer biology, protein kinase signal transduction, and genome engineering. His work bridges molecular mechanisms with potential therapeutic applications, particularly in understanding how protein kinases regulate cellular processes and how these pathways become dysregulated in cancer. His group has made significant contributions to CRISPR-based genome editing technologies and their applications in cancer research.

Analysis of his recent publications reveals a strong focus on cancer metabolism, genome maintenance mechanisms, and precision approaches to understanding genetic variants. His work demonstrates a progression from fundamental signaling mechanisms toward translational applications, with increasing emphasis on CRISPR technology and its clinical implications in cancer diagnostics and treatment.

As group leader of the Frödin Group at BRIC, he maintains an active research program with numerous international collaborations. His work has attracted attention from news outlets, policy sources, and patent applications, indicating the translational potential of his research. The group's work spans basic molecular mechanisms to potential clinical applications, with particular strength in genome editing technologies and cancer signaling pathways.